ACADIA Pharmaceuticals Inc. (OQ:ACAD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 3611 Valley Centre Dr Ste 300
SAN DIEGO CA 92130-3331
Tel: 1-858-5582871
IR: See website
Key People
Stephen R. Biggar
Independent Chairman of the Board
Ponni Subbiah
Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
Srdjan R. Stankovic
Stephen R. Davis
Director and Chief Executive Officer
Elena H. Ridloff
Executive Vice President, Chief Financial Officer
Austin D. Kim
Executive Vice President, General Counsel, and Secretary
Gudarz Davar
Executive Vice President - Head of Research and Development
Michael J. Yang
Executive Vice President, Chief Commercial Officer
Stephanie Fagan
Senior Vice President - Corporate Affairs, Chief Communications Officer
Mark Schneyer
Senior Vice President, Business Development and Chief Business Officer
Business Overview
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.
Financial Overview
For the nine months ended 30 September 2020, ACADIAPharmaceuticals Inc. revenues increased 33% to $320.7M. Netloss increased 18% to $214.8M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflects OtherResearch and development increase of 47% to $233.4M(expense), General And Administrative Expencess increase of16% to $230.4M (expense), Interest income.
Employees: 580 as of Sep 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $8,056M as of Sep 30, 2020
Annual revenue (TTM): $419.07M as of Sep 30, 2020
EBITDA (TTM): -$273.09M as of Sep 30, 2020
Net annual income (TTM): -$267.86M as of Sep 30, 2020
Free cash flow (TTM): -$144.18M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 158,978,087 as of Oct 22, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.